SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular medical applications, today provided a business update and reported financial results for the third quarter ended September 30, 2018. “REVA has achieved two technological milestones […]
Other News
InspireMD Announces Third Quarter 2018 Financial Results and Provides Corporate Update
TEL AVIV, Israel, Nov. 06, 2018 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced results for the third quarter ending September 30, 2018. Third Quarter 2018 highlights: […]
Olink Earns Acclaim from Frost & Sullivan for its Cardiac Protein Biomarker Multiplex Panels, CVD II and CVD III
LONDON, Nov. 6, 2018 /PRNewswire/ — Based on its recent analysis of the global cardiac protein biomarker research market, Frost & Sullivan recognises Olink Proteomics with the 2018 Global Enabling Technology Leadership Award for developing its cardiovascular (CV) multiplex panels—CVD II and CVD III—featuring its proprietary Proximity Extension Assay (PEA) technology. The CVD II […]
Medtronic Presents IN.PACT SFA Trial Five-Year Data and Total IN.PACT All-Subjects Analysis in VIVA Late Breaking Clinical Trials
(GLOBE NEWSWIRE via COMTEX) –New Data Continue to Reinforce IN.PACT Admiral DCB as a Durable, Frontline Option to Address Treatment Challenges in PAD DUBLIN and LAS VEGAS – November 6, 2018 – Medtronic plc (NYSE:MDT) data presented today reinforce the durability, safety, and effectiveness of the IN.PACT(TM) Admiral(TM) drug-coated balloon […]
Medical Device Startup HeartHero Announces Agreement With Vivaquant
DENVER, Nov. 6, 2018 /PRNewswire/ — Medical device startup, HeartHero has signed an agreement to license VivaQuant MDSP cardiac arrhythmia detection technology for its portable AED. HeartHero will leverage VivaQuant’s ground breaking arrhythmia technology to detect fatal heart rhythms and provide crucial lifesaving technology. In September, HeartHero won the ACEP InnovatED competition for most innovative medical device […]
BD Announces Results For 2018 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2019 Guidance
FRANKLIN LAKES, N.J., Nov. 6, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.402 billion for the fourth fiscal quarter ended September 30, 2018. This represents an increase of 39.0 percent from the prior-year period, which is primarily due to the acquisition of […]
Intact Vascular Hires Industry Veteran Steve MacKinnon as Vice President of Sales
WAYNE, Pa.–(BUSINESS WIRE)–Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that Steve MacKinnon has joined its senior management team as Vice President of Sales, effective immediately. Reporting to the CEO, Mr. MacKinnon will oversee the creation of a U.S. based sales team […]
Cardiva Medical to Present New Clinical Data on the VASCADE MVP System for Multi-Vessel Closure Following Electrophysiology Procedures
SANTA CLARA, Calif.–(BUSINESS WIRE)–Cardiva Medical, Inc., an innovator in the field of vascular closure, today announced that new data from the randomized AMBULATE study will be presented in a late-breaking session on new trials in cardiovascular care at Scientific Sessions 2018, the annual medical meeting of the American Heart Association […]
NeoChord Announces $25 Million Series D Financing to Accelerate Development of Two Transcatheter Chordal Repair Programs
ST. LOUIS PARK, Minn., Nov. 05, 2018 (GLOBE NEWSWIRE) — NeoChord, Inc., a privately-held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation, announced today that it has completed a $25 million Series D equity financing. Proceeds from the financing […]
MyoKardia to Present Clinical Evidence of Mavacamten’s Effect on Diastolic Function at 2018 American Heart Association Scientific Sessions
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced new clinical data describing mavacamten’s effect on diastolic function will be presented at the upcoming American Heart Association (AHA) Scientific Sessions […]